Bio Green Med Solution, Inc.
Business
Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals) is a fire safety equipment supplier and distributor operating in Malaysia. The company supplies and trades protective and fire safety equipment including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and safety apparel to commercial, industrial, healthcare, and residential sectors. Following its September 2025 acquisition of Fitters Sdn. Bhd., the company now operates as a specialized fire safety equipment distributor focused on the Malaysian market, with products certified by BOMBA and SIRIM.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | 747,000 | 43,000 | 420,000 | 0 | 0 | |
| Cost of sales | 609,000 | — | — | — | — | |
| Research and development | 848,000 | 7 | 19 | 20 | 15 | |
| General and administrative | 8 | 5 | — | — | — | |
| Total operating expenses | 9 | 12 | 26 | 28 | — | |
| Operating loss | −8 | −12 | −25 | −28 | −23 | |
| Foreign exchange losses | 73,000 | −54,000 | −414,000 | 233,000 | 44,000 | |
| Interest income | 62,000 | 12,000 | — | — | — | |
| Gain on deconsolidation of former subsidiary | 5 | — | — | — | — | |
| Other income, net | 354,000 | 52,000 | 50,000 | 1 | — | |
| Total other income, net | 5 | 10,000 | −98,000 | 2 | 204,000 | |
| Loss before taxes | −3 | −12 | −26 | −26 | −23 | |
| Income tax benefit / (provision) | −7,000 | 782,000 | 3 | 5 | 4 | |
| Net loss | −3 | −11 | −23 | −21 | −19 | |
| Dividend on convertible exchangeable preferred shares | −61,000 | — | −201,000 | −201,000 | −201,000 | |
| Deemed dividend on warrant exchange | −11 | — | — | — | — | |
| Net loss applicable to common shareholders | −14 | −11 | — | — | — | |
| Net loss per share - basic (common shareholders) | −6.45 | −502.46 | −26.75 | −1.9 | −2.14 | |
| Net loss per share - diluted (common shareholders) | −6.45 | −502.46 | −26.75 | −27.24 | −2.14 | |
| Weighted average common shares outstanding - basic | 2 | 22,314 | — | 11 | 9 | |
| Weighted average common shares outstanding - diluted | 2 | 22,314 | — | 11 | 9 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-08-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | — | 3 | 3 | 18 | |
| Accounts receivable | 1 | — | — | — | — | |
| Inventory | 1 | — | — | — | — | |
| Prepaid expenses and other current assets | 110,000 | — | 537,000 | 4 | 6 | |
| Total current assets | 6 | — | 4 | 7 | 24 | |
| Property and equipment, net | 137,000 | — | 3,000 | 9,000 | 32,000 | |
| Right-of-use lease asset | 12,000 | — | 5,000 | 93,000 | 142,000 | |
| Goodwill | 2 | 1,570 | — | — | — | |
| Non-current assets | 210,000 | — | 412,000 | — | — | |
| Total assets | 8 | — | 4 | 9 | 28 | |
| Accounts payable | 617,000 | — | 5 | 4 | 3 | |
| Accrued and other current liabilities | 715,000 | — | 2 | 5 | 5 | |
| Total current liabilities | 1 | — | 6 | 8 | 8 | |
| Lease liability | 2,000 | — | — | 37,000 | 106,000 | |
| Other liabilities | 9,000 | — | — | — | — | |
| Total liabilities | 1 | — | 6 | 8 | 8 | |
| Common stock, $0.001 par value; 600,000,000 shares authorized at December 31, 2025 and 100,000,000 shares authorized at December 31, 2024; 5,400,320 shares issued and outstanding at December 31, 2025 and 36,913 shares issued and outstanding at December 31, 2024 | 5,000 | — | — | 1,000 | 1,000 | |
| Additional paid-in capital | 461 | — | 438 | 430 | 423 | |
| Accumulated other comprehensive loss | −39,000 | — | −891,000 | −908,000 | −1 | |
| Accumulated deficit | −454 | — | −439 | −428 | −406 | |
| Total stockholders equity (deficit) | 7 | — | −2 | 607,000 | 16 | |
| Total liabilities and stockholders equity (deficit) | 8 | — | 4 | 9 | 28 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 5,000 | 6,000 | 31,000 | 32,000 | 43,000 | |
| Gain on deconsolidation of subsidiary | 5 | — | — | — | — | |
| Stock-based compensation | 2 | 592,000 | 1 | 2 | 1 | |
| Changes in lease liability | 2,000 | −37,000 | −69,000 | 40,000 | 172,000 | |
| Accounts receivable, net | −1 | — | — | — | — | |
| Inventory | −1 | — | — | — | — | |
| Prepaid expenses and other assets | 4 | 4 | — | — | — | |
| Accounts payable, accrued and other current liabilities | −11 | −2 | 296,000 | 3 | 3 | |
| Net cash used in operating activities | −5 | −8 | −16 | −21 | −19 | |
| Purchase of property, plant and equipment | — | — | −6,000 | −7,000 | −27,000 | |
| Net cash used in investing activities | — | — | −6,000 | −7,000 | −27,000 | |
| Proceeds, net of issuance costs, from issuing common stock and pre-funded warrants, net | 6 | 6 | 1 | — | — | |
| Payment made under the Warrant Exchange Amendment | −1 | — | — | — | — | |
| Proceeds from the exercise of stock options and warrants, net of issuance costs | — | 2 | — | — | — | |
| Payment of preferred stock dividend | −61,000 | — | −201,000 | −201,000 | −201,000 | |
| Net cash provided by in financing activities | 5 | 8 | 848,000 | 3 | 22 | |
| Effect of exchange rate changes on cash and cash equivalents | −126,000 | −73,000 | 303,000 | −378,000 | −17,000 | |
| Net increase (decrease) in cash and cash equivalents | 368,000 | −241,000 | −15 | −18 | 3 | |
| Issuance of shares in acquisition of Fitters Sdn. Bhd. | 4 | — | — | — | — | |
| Warrant Exchange | 11 | — | — | — | — | |
| Interest | 68,000 | 96,000 | 266,000 | 211,000 | 17,000 | |
| Research & development tax credits | — | 4 | 5 | 3 | 1 | |
| Interest | 7,000 | — | — | — | — | |
| Taxes | 18,000 | 2,000 | 2,000 | 2,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Bio Green Med Solution, Inc.'s CIK number?
Bio Green Med Solution, Inc.'s SEC CIK number is 0001130166 (1130166). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Bio Green Med Solution, Inc.'s SEC filings?
All of Bio Green Med Solution, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Bio Green Med Solution, Inc. last report earnings?
Bio Green Med Solution, Inc. (BGMSP) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-023117). This is Bio Green Med Solution, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Bio Green Med Solution, Inc.'s most recent earnings 8-K?
Bio Green Med Solution, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001493152-26-023117. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Bio Green Med Solution, Inc.'s latest earnings 8-K →
Look up any company's CIK number →